Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Gerstoft

Showing results (291-300 of 306) with videos related to

Pageof 31
Sort By:
Journal of Viral Hepatitis|May 28, 2022
Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in DenmarkSigne Bollerup, Sofie Hallager, Frederik Engsig, et al.
Journal of Hepatocellular Carcinoma|October 25, 2022
Incidence of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis and Prognostic Accuracy of the PAGE-B HCC Risk Score in a Low Endemic Hepatitis B Virus Infected PopulationSigne Bollerup, Frederik Engsig, Sofie Hallager, et al.
AIDS (London, England)|July 18, 2022
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimensWendy P Bannister, T Christopher Mast, Stéphane de Wit, et al.
Clinical Epidemiology|July 26, 2022
Ischemic Heart Disease in Chronic Hepatitis B: A Danish Nationwide Cohort StudyFrederik Faergemann Lau, Signe Bollerup, Frederik Engsig, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Ebiomedicine|June 18, 2023
Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort studyLine Dam Heftdal, Laura Pérez-Alós, Rasmus Bo Hasselbalch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2019
Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus TreatmentAmanda Mocroft, Jens Lundgren, Jan Gerstoft, et al.
Journal of Hepatology|August 21, 2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trialJan Sperl, Gabor Horvath, Waldemar Halota, et al.
Medicine|July 20, 2018
Classification of death causes after transplantation (CLASS): Evaluation of methodology and initial resultsNeval Ete Wareham, Caspar Da Cunha-Bang, Álvaro H Borges, et al.
AIDS (London, England)|December 23, 2024
Humoral response 24 months after the first COVID-19 vaccination in people with HIV with and without diabetesLouise Bering, Line Dam Heftdal, Safura-Luise Heidari, et al.
Pageof 31

Showing results (291-300 of 306) with videos related to

Sort By:
Pageof 31
Journal of Viral Hepatitis|May 28, 2022
Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in DenmarkSigne Bollerup, Sofie Hallager, Frederik Engsig, et al.
Journal of Hepatocellular Carcinoma|October 25, 2022
Incidence of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis and Prognostic Accuracy of the PAGE-B HCC Risk Score in a Low Endemic Hepatitis B Virus Infected PopulationSigne Bollerup, Frederik Engsig, Sofie Hallager, et al.
AIDS (London, England)|July 18, 2022
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimensWendy P Bannister, T Christopher Mast, Stéphane de Wit, et al.
Clinical Epidemiology|July 26, 2022
Ischemic Heart Disease in Chronic Hepatitis B: A Danish Nationwide Cohort StudyFrederik Faergemann Lau, Signe Bollerup, Frederik Engsig, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Ebiomedicine|June 18, 2023
Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort studyLine Dam Heftdal, Laura Pérez-Alós, Rasmus Bo Hasselbalch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2019
Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus TreatmentAmanda Mocroft, Jens Lundgren, Jan Gerstoft, et al.
Journal of Hepatology|August 21, 2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trialJan Sperl, Gabor Horvath, Waldemar Halota, et al.
Medicine|July 20, 2018
Classification of death causes after transplantation (CLASS): Evaluation of methodology and initial resultsNeval Ete Wareham, Caspar Da Cunha-Bang, Álvaro H Borges, et al.
AIDS (London, England)|December 23, 2024
Humoral response 24 months after the first COVID-19 vaccination in people with HIV with and without diabetesLouise Bering, Line Dam Heftdal, Safura-Luise Heidari, et al.
Pageof 31